We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.17B
1-Year Est. Return
92.19%
This Fund
S&P 500
This Quarter
Est. Return
+10.53%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$6.39B
AUM Growth
+$1.46B
(+30%)
Cap. Flow
+$92.4M
Cap. Flow
% of AUM
1.45%
Top 10 Holdings %
Top 10 Hldgs %
30%
Holding
130
New
34
Increased
32
Reduced
37
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$114M |
| 2 |
Centene
CNC
|
+$75.1M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$67.2M |
| 4 |
Spotify
SPOT
|
+$55.4M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$51.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$198M |
| 2 |
Microsoft
MSFT
|
+$102M |
| 3 |
Baxter International
BAX
|
+$84.8M |
| 4 |
Molina Healthcare
MOH
|
+$65.2M |
| 5 |
UnitedHealth
UNH
|
+$50.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.2% |
| 2 | Miscellaneous | 20.28% |
| 3 | Technology | 9.35% |
| 4 | Communication Services | 7.21% |
| 5 | Consumer Discretionary | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Invesco QQQ Trust
QQQ
$489B
| $412M | 6.45% |
+2,398,900
| New | +$402M |
|
2
Jazz Pharmaceuticals
JAZZ
$16B
| $213M | 3.34% |
1,238,906
+103,379
| +9% | +$16.9M |
|
3
PUT
iShares Russell 2000 ETF
IWM
$81.2B
| $203M | 3.18% |
+1,239,300
| New | +$198M |
|
|
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $192M | 3% |
5,079,770
-246,901
| -5% | -$9.44M |
|
|
AERI
5
DELISTED
Aerie Pharmaceuticals
AERI
| $184M | 2.88% |
2,720,218
-112,785
| -4% | -$6.31M |
|
6
Elevance Health
ELV
$88.4B
| $168M | 2.64% |
707,244
+46,374
| +7% | +$10.7M |
|
7
Viatris
VTRS
$19.4B
| $162M | 2.54% |
4,480,720
-143,359
| -3% | -$5.62M |
|
8
Tenet Healthcare
THC
$21.3B
| $146M | 2.28% |
4,336,946
+786,785
| +22% | +$24.5M |
|
9
PUT
iShares MSCI Emerging Markets ETF
EEM
$31.9B
| $130M | 2.04% |
+3,005,700
| New | +$139M |
|
|
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
| $106M | 1.66% |
+2,337,225
| New | +$114M |
|
11
Alphabet (Google) Class A
GOOGL
$4.14T
| $101M | 1.59% |
1,795,480
+751,480
| +72% | +$40.9M |
|
12
Zimmer Biomet
ZBH
$18.7B
| $99.7M | 1.56% |
921,454
+3,290
| +0.4% | +$358K |
|
13
Pacira BioSciences
PCRX
$1.05B
| $99.7M | 1.56% |
3,110,213
+1,405,605
| +82% | +$48.5M |
|
14
Salesforce
CRM
$213B
| $98.8M | 1.55% |
724,231
+168,423
| +30% | +$21.5M |
|
|
ESPR
15
DELISTED
Esperion Therapeutics
ESPR
| $96.4M | 1.51% |
2,460,157
+1,330,159
| +118% | +$67.2M |
|
16
Puma Biotechnology
PBYI
$493M
| $94.5M | 1.48% |
1,596,783
-435,836
| -21% | -$25.3M |
|
17
Humana
HUM
$48.2B
| $92M | 1.44% |
309,101
-11,349
| -4% | -$3.32M |
|
|
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $90.3M | 1.41% |
1,819,315
+869,404
| +92% | +$42.1M |
|
19
DaVita
DVA
$11.7B
| $89.2M | 1.4% |
1,285,000
+659,997
| +106% | +$44.1M |
|
20
Baidu
BIDU
$33.7B
| $89.2M | 1.4% |
367,146
+138,324
| +60% | +$34.4M |
|
21
Revvity
RVTY
$14.5B
| $85.1M | 1.33% |
1,161,817
+80,310
| +7% | +$6.02M |
|
22
Abbott
ABT
$187B
| $81.6M | 1.28% |
1,337,288
-419,508
| -24% | -$25.4M |
|
|
23
Centene
CNC
$33.1B
| $80.2M | 1.26% |
+1,302,436
| New | +$75.1M |
|
24
Penumbra
PEN
$12.7B
| $79.4M | 1.24% |
574,400
-72,586
| -11% | -$10.3M |
|
|
MDCO
25
DELISTED
Medicines Co
MDCO
| $76.7M | 1.2% |
2,088,997
-114,334
| -5% | -$3.72M |
|
Similar funds
JC
PRS
MK
HCP
EC
M
CCM
VFP
PFM Health Sciences's Q2 2018 Portfolio in Review
As of Q2 2018, PFM Health Sciences held 130 positions worth $6.39B, up 30% from $4.92B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
PFM Health Sciences's Q2 2018 filing shows 34 new, 32 increased, 37 reduced and 15 closed positions. Its largest new stake was Clovis Oncology, Inc.: 2,337,225 shares worth $106M. The largest sale was Bristol-Myers Squibb, an estimated $198M.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 70% a quarter earlier, followed by Miscellaneous and Technology.
- PFM Health Sciences's largest Q2 2018 buy was Clovis Oncology, Inc.: 2,337,225 shares worth $106M.
- PFM Health Sciences added most to Esperion Therapeutics in Q2 2018, an estimated $67.2M increase.
- PFM Health Sciences's biggest Q2 2018 reduction was Microsoft, cutting an estimated $102M.
- PFM Health Sciences fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $198M.
- PFM Health Sciences's ten largest holdings make up 30% of its $6.39B portfolio in Q2 2018.
- PFM Health Sciences opened 34 new positions and closed 15 in Q2 2018.
- PFM Health Sciences's portfolio value rose 30% quarter-over-quarter to $6.39B.
Based on PFM Health Sciences's 13F filing for Q2 2018, filed 14 Aug 2018.